<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03731559</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 254</org_study_id>
    <nct_id>NCT03731559</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Pharmacokinetics of DTG With RIF</brief_title>
  <official_title>Efficacy, Safety and Pharmacokinetics of Dolutegravir 50 mg Once Daily With Food Versus Dolutegravir 50 mg Twice Daily in HIV/TB Co-infected Patients Receiving Rifampin-based Antituberculosis Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chest Division, Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Infectious Disease, Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bamrasnaradura Infectious Diseases Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bhumibol Adulyadej Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Infectious Disease Taksin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Infectious Disease Chiangrai Prachanukroh Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Infectious Disease Chonburi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Infectious Disease Buddhachinaraj Phitsanulok Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud UMC Nijmegen, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Disease Control, Ministry of Public Health (MOPH), Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of the project is to evaluate optimal DTG dose for the combined treatment of&#xD;
      TB and HIV infections with RIF based anti-TB therapy. This Stage II trial will determine&#xD;
      precisely the PK parameters of DTG in combination with RIF regimen in Thai HIV/TB co-infected&#xD;
      patients. After the optimal dose of DTG has been found, it will be further tested in a larger&#xD;
      Stage III trial to assess its safety, tolerability and efficacy when used with RIF based&#xD;
      regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Stage II, randomized, open-label study describing the efficacy and safety of DTG 50&#xD;
      mg OD with food and DTG 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF&#xD;
      based anti-TB therapy. The study will be conducted in approximately 200 HIV-1 infected&#xD;
      individuals who are ART-na√Øve and newly diagnosed with probable or confirmed pulmonary,&#xD;
      pleural, or lymph node (LN) Mycobacterium TB (MTB) taking RIF-containing first-line TB&#xD;
      treatment. Subjects should have confirmed RIF-sensitive MTB infection as determined by&#xD;
      GeneXpert (or equivalent approved molecular test) or mycobacterial culture.&#xD;
&#xD;
      The study is comprised two different stages:&#xD;
&#xD;
        1. Stage1, investigators will test the safety and tolerability, as well as Pharmacokinetics&#xD;
           (PK), of two different doses of dolutegravir co-administered with standard anti-TB&#xD;
           treatment. Overall, 40 HIV/TB patients will be enrolled. They will be randomized to 2&#xD;
           groups (DTG 50 mg with food and DTG 50 mg BID). Intensive PK of DTG will be performed at&#xD;
           week 4. Interim analysis will be performed if all 40 cases completed 12 weeks and 24&#xD;
           weeks. Premature study termination will be set for&#xD;
&#xD;
             1. proportion of HIV RNA &lt; 50 copies/ml at week 24 between 2 group is different &gt; 20%&#xD;
&#xD;
             2. DTG 50 mg with food has geometric mean DTG Ctrough &lt; 0.3 mg/L If there is no&#xD;
                premature study termination met, the study will move to stage 2. Stage 2 will only&#xD;
                be recruited if two different doses of dolutegravir are well tolerated and safe.&#xD;
&#xD;
        2. Stage 2: 160 HIV/TB patients will be enrolled. They will be randomized to 2 groups (DTG&#xD;
           50 mg with food and DTG 50 mg BID). DTG concentration will be performed at week 4 and&#xD;
           48. Interim analysis will be performed if all 200 cases completed 24 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of subjects from the ITT analysis population with plasma HIV-1 RNA &lt;50 c/mL at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The primary efficacy endpoint is the proportion of subjects from the ITT analysis population with plasma HIV-1 RNA &lt;50 c/mL at Week 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of DTG concentration between DTG 50 mg with food OD and DTG 50 mg BID</measure>
    <time_frame>Week 4</time_frame>
    <description>AUC of DTG concentration between DTG 50 mg with food OD and DTG 50 mg BID</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of DTG concentration between DTG 50 mg with food OD and DTG 50 mg BID</measure>
    <time_frame>Week 4</time_frame>
    <description>Cmax of DTG concentration between DTG 50 mg with food OD and DTG 50 mg BID</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of DTG concentration between DTG 50 mg with food OD and DTG 50 mg BID</measure>
    <time_frame>Week 4</time_frame>
    <description>Cmin of DTG concentration between DTG 50 mg with food OD and DTG 50 mg BID</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral clearance of DTG concentration between DTG 50 mg with food OD and DTG 50 mg BID</measure>
    <time_frame>Week 4</time_frame>
    <description>Oral clearance of DTG concentration between DTG 50 mg with food OD and DTG 50 mg BID</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with plasma HIV-1 RNA &lt;50 c/mL at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Proportion of subjects with plasma HIV-1 RNA &lt;50 c/mL at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4+ counts from baseline to Week 24 and Week 48</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <description>Changes in CD4+ counts from baseline to Week 24 and Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of disease progression</measure>
    <time_frame>Week 48</time_frame>
    <description>Incidence of disease progression (HIV-associated conditions, new AIDS diagnoses, and death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects that have completed TB treatment</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of subjects that have completed TB treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects that are cured from TB</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of subjects that are cured from TB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects that have relapsed</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of subjects that have relapsed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects that have defaulted</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of subjects that have defaulted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB outcome in terms of cure</measure>
    <time_frame>Week 48</time_frame>
    <description>Number of participants that have been cured of TB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB outcome in terms of relapse</measure>
    <time_frame>Week 48</time_frame>
    <description>Number of participants with relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB outcome in terms of treatment failure due to TB resistance</measure>
    <time_frame>Week 48</time_frame>
    <description>Number of participants with treatment failure due to TB resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB outcome in terms of incidence</measure>
    <time_frame>Week 48</time_frame>
    <description>Incidence of all AEs, SAEs, and laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB outcome in terms of severity</measure>
    <time_frame>Week 48</time_frame>
    <description>Severity of all AEs, SAEs, and laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>discontinuation from the study</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of subjects who permanently discontinued randomization arm due to AEs or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>discontinuation from the study drugs</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of subjects who temporarily discontinued the study drugs and/or TB therapy due to AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with TB-associated IRIS</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of subjects with TB-associated IRIS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of DTG at Weeks 4 (with RIF) and 48 (without RIF)</measure>
    <time_frame>Weeks 4 and 48</time_frame>
    <description>AUC of DTG at Weeks 4 (with RIF) and 48 (without RIF) will be analyzed using population PK modeling approach to estimate AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of DTG at Weeks 4 (with RIF) and 48 (without RIF)</measure>
    <time_frame>Weeks 4 and 48</time_frame>
    <description>Cmax of DTG at Weeks 4 (with RIF) and 48 (without RIF) will be analyzed using population PK modeling approach to estimate Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of DTG at Weeks 4 (with RIF) and 48 (without RIF)</measure>
    <time_frame>Weeks 4 and 48</time_frame>
    <description>Ctrough of DTG at Weeks 4 (with RIF) and 48 (without RIF) will be analyzed using population PK modeling approach to estimate Ctrough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of subjects with plasma HIV-1 RNA &lt;50 c/mL at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>proportion of subjects with plasma HIV-1 RNA &lt;50 c/mL at Week 48 (viral suppression)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>HIV/TB Coinfection</condition>
  <arm_group>
    <arm_group_label>DTG 50 mg OD with food</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DTG 50 mg OD with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DTG 50 mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DTG 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG 50 mg OD with food</intervention_name>
    <description>Dolutegravir 50 mg once daily with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy</description>
    <arm_group_label>DTG 50 mg OD with food</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG 50 mg BID</intervention_name>
    <description>Dolutegravir 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.</description>
    <arm_group_label>DTG 50 mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. documented HIV positive&#xD;
&#xD;
          2. Aged &gt;18 years&#xD;
&#xD;
          3. ARV na√Øve (previous exposure to ARV for &lt; 2 weeks)&#xD;
&#xD;
          4. Any CD4 cell count&#xD;
&#xD;
          5. ALT &lt;5 times ULN&#xD;
&#xD;
          6. estimated GFR&gt;60 ml/min/1.73m2&#xD;
&#xD;
          7. Hemoglobin &gt;7 mg/L&#xD;
&#xD;
          8. TB is diagnosed and there is a plan to receive stable doses of RIF containing anti-TB&#xD;
             therapy for at least another 4 week period after initiation of ART&#xD;
&#xD;
          9. No other active OI (CDC class C event) except oral candidiasis or disseminated MAC&#xD;
&#xD;
         10. Body weight &gt;40kg&#xD;
&#xD;
         11. Able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have documented history of HIV treatment failure or HIV mutation to NRTI, NNRTI,&#xD;
             and/or INIs&#xD;
&#xD;
          2. Have previously treated for tuberculosis&#xD;
&#xD;
          3. Currently using immunosuppressive agents.&#xD;
&#xD;
          4. Currently using any prohibited medications that can affect the pharmacokinetics of the&#xD;
             study drug such as phenobarbital, and carbamazepine&#xD;
&#xD;
          5. Currently using alcohol or illicit substances that may affect the conduct of the trial&#xD;
             as per the opinion of the site Principal Investigator&#xD;
&#xD;
          6. Unlikely to be able to remain in the follow-up period as defined by the protocol&#xD;
&#xD;
          7. Patients with proven or suspected acute hepatitis. Patients with chronic viral&#xD;
             hepatitis are eligible provided ALT, AST &lt; 5 x ULN.&#xD;
&#xD;
          8. Have Karnofsky performance score &lt;30%&#xD;
&#xD;
          9. Have TB meningitis, bone/joints (due to prolonged use of anti-TB drug)&#xD;
&#xD;
         10. Pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anchalee Avihingsanon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIV-NAT, Thai Red Cross - AIDS Research Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>June Ohata, BS</last_name>
    <phone>6626523040</phone>
    <phone_ext>147</phone_ext>
    <email>juneohata4@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Infectious Disease Chiangrai Prachanukroh Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <state>Chiangrai</state>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suwimol Khusuwan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Suwimol Khusuwan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klang Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10100</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Praniti Danpornprasert, MD</last_name>
    </contact>
    <investigator>
      <last_name>Praniti Danpornprasert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bhumibol Adulyadej Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10220</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Fujitnirun, MD</last_name>
      <email>fujitnirunchris@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chris Fujitnirun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chest Division, Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamol Kawkitinarong, MD</last_name>
      <email>kamonkaw@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Kamol Kawkitinarong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIV-NAT, Thai Red Cross - AIDS Research Centre</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anchalee Avihingsanon, MD, PhD</last_name>
      <phone>662 652 3040</phone>
      <email>anchalee.a@hivnat.org</email>
    </contact>
    <investigator>
      <last_name>Anchalee Avihingsanon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sivaporn Gatechompol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Win Min Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akarin Hiransuthikul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infectious Disease, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gompol Suwanpimolkul, MD</last_name>
      <email>sgompol@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gompol Suwanpimolkul</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Opass Putcharoen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Taksin Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10600</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Supannee Jirajariyavet, MD</last_name>
      <email>jsupunee@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Supannee Jirajariyavet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Chonburi Hospital</name>
      <address>
        <city>Chon Buri</city>
        <zip>20000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Palakorn Panarat, MD</last_name>
    </contact>
    <investigator>
      <last_name>Palakorn Panarat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bamrasnaradura Infectious Diseases Institute</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weerawat Manosuthi, MD</last_name>
      <email>drweerawat@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Weerawat Manosuthi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Buddhachinaraj Phitsanulok Hospital</name>
      <address>
        <city>Phitsanulok</city>
        <zip>65000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pornpit Treebupachatsakul, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pornpit Treebupachatsakul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Dolutegravir</keyword>
  <keyword>HIV/TB co-infected patients</keyword>
  <keyword>rifampin-based antituberculosis therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

